Serial gadolinium-enhanced MRI in untreated patients with acute optic neuritis: Implications for natural history

Acta Neurologica Scandinavica

Volumn 96, Issue 1, 1997, Pages 22-27

  Frederiksen, J L ^a   Larsson, H B W ^b   Jensen, C ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Blood brain barrier; Follow up; Gadolinium DTPA; MRI; Multiple sclerosis; Optic neuritis

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; DEMYELINATING DISEASE; DIAGNOSTIC IMAGING; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE;

EID: 0030837665     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1997.tb00233.x     Document Type: Article

References (27)

1. GONZALEZ-SCARANO F, GROSSMANN RI, GALETTA S, ATLAS SW, SILBERBERG DH. Multiple sclerosis disease activity correlates with Gadolinium-enhanced magnetic resonance imaging. Ann Neurol 1987: 21: 300-6.
2. MILLER DH, RUDGE P, JOHNSON G et al. Serial Gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988: 111: 927-39.
3. LARSSON HBW, STUBGAARD M, FREDERIKSEN J, JENSEN M, HENRIKSEN O, PAULSON OB. Quantitation of blood-brain barrier defect by magnetic resonance imaging and Gadolinium-DTPA in patients with multiple sclerosis and brain tumours. Magn Reson Med 1990: 16: 117-31.
4. KERMODE AG, TOFTS PS, THOMPSON AJ et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with Gadolinium-DTPA enhancement. Neurology 1990: 40: 229-35.
5. BASTIANELLO S, POZZILLI C, BERNARDI S et al. Serial study of Gadolinium MRI enhancement in multiple sclerosis. Neurology 1990: 40: 591-5.
6. HARRIS JO, FRANK JA, PATRONAS N, MCFARLIN DE, MCFARLAND HF. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history. Ann Neurol 1991: 29: 548-55.
7. THOMPSON AJ, KERMODE AG, WICKS D et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991: 29: 53-62.
8. THOMPSON AJ, MILLER D, YOUL B et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992: 42: 60-3.
9. GUTTMANN CRG, AHN SS, HSU L, KIKINIS R, JOLESZ FA. The evolution of multiple sclerosis lesions on serial MRI. AJNR Am J Neuroradiol 1995: 16: 1481-91.
10. FREDERIKSEN JL, LARSSON HBW, HENRIKSEN O, OLESEN J. Magnetic resonance imaging of the brain in acute isolated optic neuritis. Acta Neurol Scand 1989: 80: 512-17.
11. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983: 13: 227-31.
12. KURTZKE JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983: 33: 1444-52.
13. CHRISTIANSEN P, FREDERIKSEN JL, HENRIKSEN O, LARSSON HBW. Gd-DTPA-enhanced lesions in the brain in patients with acute optic neuritis. Acta Neurol Scand 1992: 85: 141-6.
14. SMITH ME, STONE LA, ALBERT PS et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993: 33(5): 480-9.
15. MERANDI SF, KUDRYK BT, MURTAGH FR, ARRINGTON JA. Contrast-enhanced MR imaging of optic nerve lesions in patients with acute optic neuritis. AJNR Am J Neuroradiol 1991: 12: 923-6.
16. BARKHOF F, SCHELTENS P, FREQUIN ST et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992: 159: 1041-7.
17. MCFARLAND HF, FRANK JA, ALBERT PS et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 1992: 32: 758-66.
18. STONE LA, SMITH ME, ALBERT PS et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender and age. Neurology 1995: 45: 1122-6.
19. FREDERIKSEN JL, LARSSON HBW, CHRISTIANSEN P, SELLEBJERG FT, OLESEN J. Blood-brain barrier impairment in acute optic neuritis evaluated by Gadolinium-DTPA enhanced MRI and CSF studies. Eur J Neurol 1996: 3: 560-6.
20. MILLER DH, BARKHOF F, NAUTA JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993: 116: 1077-94.
21. ADAMS CWM, POSTON RN, BUK SJ. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J Neurol Sci 1989: 92: 291-306.
22. KATZ D, TAUBENBERGER J, RAINE C, MCFARLIN D, MCFARLAND HF. Gadolinium-enhancing lesions on magnetic resonance imaging: neuropathological findings. Ann Neurol 1990: 28: 243.
23. NESBIT GM, FORBES GS, SCHEITHAUER BW, OKAZAKI H, RODRIGUEZ M. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991: 180: 467-74.
24. LASSMANN H, SUCHANEK G, OZAWA K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994: 36: 542-6.
25. KIDD D, THOMPSON AJ, KENDALL BE, MILLER DH, MCDONALD WI. Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994: 57: 1070-2.
26. FILIPPI M, CAMPI A, MARTINELLI V et al. Comparison of triple dose versus standard dose Gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995: 59: 540-4.
27. YOUL BD, TURANO G, MILLER DH et al. The pathophysiology of acute optic neuritis. An association of Gadolinium leakage with clinical and electrophysiological deficits. Brain 1991: 114: 2437-50.